{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:55:58Z","timestamp":1779904558855,"version":"3.53.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T00:00:00Z","timestamp":1171497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2007,2,15]],"date-time":"2007-02-15T00:00:00Z","timestamp":1171497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s00392-007-0487-y","type":"journal-article","created":{"date-parts":[[2007,2,10]],"date-time":"2007-02-10T15:05:52Z","timestamp":1171119952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of heart failure with ACE inhibitors and beta-blockers"],"prefix":"10.1007","volume":"96","author":[{"given":"Iwan C. C.","family":"van der Horst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,15]]},"reference":[{"key":"487_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi166","volume":"26","author":"Swedberg","year":"2005","unstructured":"Swedberg K, Cleland JG, Dargie H et al (2005) Guidelines for the diagnosis and treatment of chronic heart failure:executive summary (update 2005):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115\u20131140","journal-title":"Eur Heart J"},{"key":"487_CR2","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667\u20131675","journal-title":"N Engl J Med"},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"Pfeffer","year":"2003","unstructured":"Pfeffer MA, Swedberg K, Granger CB et al (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 362(9386):759\u2013766","journal-title":"Lancet"},{"key":"487_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"487_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J et al; of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"487_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1053\/euhj.1997.0840","volume":"19","author":"Van Veldhuisen","year":"1998","unstructured":"Van Veldhuisen DJ, Boomsma F, De Kam PJ et al (1998) Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure. Eur Heart J 19:753\u2013760","journal-title":"Eur Heart J"},{"key":"487_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0167-5273(00)00172-8","volume":"73","author":"Teisman","year":"2000","unstructured":"Teisman ACH, Van Veldhuisen DJ, Boomsma F et al (2000) Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol 73:7\u201312","journal-title":"Int J Cardiol"},{"key":"487_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R et al (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:457\u2013465","journal-title":"J Endocrinol"},{"key":"487_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/joe.1.06017","volume":"186","author":"McConnel","year":"2005","unstructured":"McConnel JM, Davies E (2005) The new biology of aldosterone. J Endocrinol 186:1\u201320","journal-title":"J Endocrinol"},{"key":"487_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.2005-0004","volume":"26","author":"Funder","year":"2005","unstructured":"Funder JW (2005) The nongenomic actions of aldosterone. Endocrin Rev 26:313\u2013321","journal-title":"Endocrin Rev"},{"key":"487_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/hrt.2003.017368","volume":"90","author":"Mcdonald","year":"2004","unstructured":"Mcdonald JE, Kennedy N, Struthers AD (2004) Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90:765\u2013770","journal-title":"Heart"},{"key":"487_CR12","doi-asserted-by":"publisher","first-page":"H2176","DOI":"10.1152\/ajpheart.00186.2006","volume":"290","author":"Pitt","year":"2006","unstructured":"Pitt GS, Pitt B (2006) Aldosterone, ion channels and sudden death:another piece of the circle? Am J Physiol Heart Circ Physiol 290:H2176\u20132177","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"487_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"Pitt","year":"2005","unstructured":"Pitt B, White H, Nicolau J et al (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46:425\u2013431","journal-title":"J Am Coll Cardiol"},{"key":"487_CR14","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1056\/NEJMoa043938","volume":"352","author":"Solomon","year":"2005","unstructured":"Solomon SD, Zelenkofske SD, McMurray JJ et al (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581\u20132588","journal-title":"N Engl J Med"},{"key":"487_CR15","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa041489","volume":"351","author":"Hohnloser","year":"2004","unstructured":"Hohnloser SH, Kuck KH, Dorian P et al (2004) DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351:2481\u20132488","journal-title":"N Engl J Med"},{"key":"487_CR16","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","unstructured":"Hayashi M, Tsutamoto T, Wada A et al (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodelling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior myocardial infarction. Circulation 107:2559\u20132565","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-007-0487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-007-0487-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-007-0487-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-007-0487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T17:12:55Z","timestamp":1630429975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-007-0487-y"}},"subtitle":["What is next? Aldosterone receptor antagonists?"],"short-title":[],"issued":{"date-parts":[[2007,2,15]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1007\/s00392-007-0487-y","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,15]]},"assertion":[{"value":"14 July 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"193"}}